About Oncolytics Biotech (TSE:ONC)
Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.
Industry, Sector and Symbol:
- Trailing EPS: C($0.13)
- Return on Equity: -161.95%
- Return on Assets: -123.71%
- Outstanding Shares: 139,426,000
Frequently Asked Questions for Oncolytics Biotech (TSE:ONC)
What is Oncolytics Biotech's stock symbol?
Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."
When will Oncolytics Biotech make its next earnings announcement?
Where is Oncolytics Biotech's stock going? Where will Oncolytics Biotech's stock price be in 2017?
2 analysts have issued 1 year price objectives for Oncolytics Biotech's stock. Their forecasts range from C$1.50 to C$1.50. On average, they anticipate Oncolytics Biotech's stock price to reach C$1.50 in the next year. View Analyst Ratings for Oncolytics Biotech.
Who are some of Oncolytics Biotech's key competitors?
Some companies that are related to Oncolytics Biotech include XOMA Corporation (XOMA), Osiris Therapeutics (OSIR), Anavex Life Sciences Corp. (AVXL), Trillium Therapeutics (TRIL), Aevi Genomic Medicine (GNMX), ContraFect Corporation (CFRX), Concordia International Corp. (CXR), Soligenix (SNGX), Senesco Technologies (SVON), Mateon Therapeutics (MATN), Windtree Therapeutics (WINT), Affymax (AFFY), TetraLogic Pharmaceuticals Corporation (TLOG), Cubist Pharmaceuticals (CBST), Idenix Pharmaceuticals (IDIX) and Onyx Pharmaceuticals (ONXX).
Who are Oncolytics Biotech's key executives?
Oncolytics Biotech's management team includes the folowing people:
- Wayne F. Pisano, Chairman of the Board
- Matthew C. Coffey Ph.D., President, Chief Executive Officer, Chief Operating Officer, Director
- Kirk J. Look, Chief Financial Officer
- George M. Gill M.D., Senior Vice President - Regulatory Affairs & Chief Safety Officer
- Mary Ann Dillahunty J.D., Vice President - Intellectual Property
- Andres A. Gutierrez, Chief Medical Officer
- Alan J. Tuchman M.D., Chief Neuro Oncology Research Officer (Age 69)
- Deborah Brown, Director
- Angela Frances Holtham, Director
- Edwin Levy Ph.D., Director
How do I buy Oncolytics Biotech stock?
Shares of Oncolytics Biotech and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Oncolytics Biotech's stock price today?
One share of Oncolytics Biotech stock can currently be purchased for approximately C$0.73.
How big of a company is Oncolytics Biotech?
Oncolytics Biotech has a market capitalization of C$106.93 million.
How can I contact Oncolytics Biotech?
Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The company can be reached via phone at +1-403-6707380.
MarketBeat Community Rating for Oncolytics Biotech (TSE ONC)MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Oncolytics Biotech (TSE:ONC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||C$1.50|
Consensus Price Target History for Oncolytics Biotech (TSE:ONC)
Analysts' Ratings History for Oncolytics Biotech (TSE:ONC)
(Data available from 11/22/2015 forward)
|4/13/2017||BMO Capital Markets||Boost Price Target||Outperform||C$1.00 -> C$1.50|
|4/13/2017||Royal Bank Of Canada||Boost Price Target||Outperform||C$1.00 -> C$1.50|
Earnings History and Estimates Chart for Oncolytics Biotech (TSE:ONC)
Earnings History by Quarter for Oncolytics Biotech (TSE ONC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/9/2018|| || || || || || || || |
Earnings Estimates for Oncolytics Biotech (TSE:ONC)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Oncolytics Biotech (TSE:ONC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Oncolytics Biotech (TSE ONC)
Insider Trades by Quarter for Oncolytics Biotech (TSE ONC)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/26/2015||Angela Frances Holtham||Director||Buy||5,000||C$0.89||C$4,450.00|
Latest Headlines for Oncolytics Biotech (TSE ONC)
Financials are not available for this stock.
Oncolytics Biotech (TSE ONC) Chart for Wednesday, November, 22, 2017